Close

New Molecular Target For Cancer Therapy Found Through Study

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

China Unveils Innovative Drugs Policy to Boost Development

The National Health Commission and China's National Healthcare Security...

Ensuring optimal product integrity with pharmaceutical preservation strategies

Preserving the potency of pharmaceutical products is paramount in...

How Stem Cell Therapy Works for the Individual

Stem cell therapy has emerged as one of the...

Tjoapack Expands Injectable Packaging Capabilities Globally

Increased Capabilities in the United States Tjoapack is finishing up...

The Ohio State University Comprehensive Cancer Center, Richard J. Solove Research Institute, and James Cancer Hospital have discovered a new molecular therapeutic target that could lead to the development of new cancer treatments with fewer side effects.

Previous research has revealed that VEGF-A, a powerful cytokine (signalling protein), and dopamine, a neurotransmitter/neurohormone, play critical roles in a variety of physiologic and pathologic activities. In this new laboratory study, Dr. Sujit Basu and colleagues undertook extensive preclinical examination of VEGF-A as a focus for the creation of new cancer therapeutic techniques. For the first time, the researchers discovered that VEGF-A can increase the expression of dopamine D2 receptors on endothelial cells, which can then be energised to prevent the growth of new blood vessels that drive the growth and spread of diseases like colon cancer, endometriosis, and ovarian hyperstimulation syndromeAngiogenesis is the formation of new blood vessels. The Journal of Cell Science published this research.

It is a very persuasive revelation that opens new passageways for designing efficient new anti-angiogenic therapies in the treatment of cancer and other diseases in which VEGF-A is a recognised driver of disease emergence and expansion, said Basu, The Ohio State University College of Medicine professor and a member of the OSUCCC-James’ Translational Therapeutics Program.

Selective dopamine D2 receptor agonists, unlike currently available anti-VEGF-A anti-angiogenic medicines, are affordable and have well-established and tolerable side effects, according to Basu.

The present anti-VEGF-A anti-angiogenic compounds in clinics have substantial side effects, whereas these treatments do not. Therefore, they feel they deserve more research as a therapy option for cancer and other ailments involving the VEGF-A pathway, Basu explained. Clinical studies for these medications are expected to begin soon, according to researchers.

Latest stories

Related stories

China Unveils Innovative Drugs Policy to Boost Development

The National Health Commission and China's National Healthcare Security...

Ensuring optimal product integrity with pharmaceutical preservation strategies

Preserving the potency of pharmaceutical products is paramount in...

How Stem Cell Therapy Works for the Individual

Stem cell therapy has emerged as one of the...

Tjoapack Expands Injectable Packaging Capabilities Globally

Increased Capabilities in the United States Tjoapack is finishing up...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back